CEPI will provide funding of up to $90 million to support the development of vaccine candidates which is based on BioNTech's mRNA technology. BioNTech will initiate a early-to-mid stage trial for the vaccine BNT166 for the prevention of mpox.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/KhrUIS9
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» BioNTech partners with CEPI to advance development of mpox vaccine
https://ift.tt/V6lhzIJ
No comments:
Post a Comment